MoneyWorks4Me

Hikal - Quaterly Results

12 Feb 2026 Evaluate
The December 2025 quarter revenue stood at Rs. 4943.00 millions, up 10.41% as compared to Rs. 4477.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2025 is Rs. -59.00 millions as compared to Net Profit of Rs. 173.00 millions of corresponding quarter ended December 2024Operating profit surged to 855.00 millions from the corresponding previous quarter of 758.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 4943.00 4477.00 10.41 11932.00 13074.00 -8.73 18598.00 17846.00 4.21
Other Income 28.00 36.00 -22.22 57.00 45.00 26.67 50.00 25.00 100.00
PBIDT 855.00 758.00 12.80 1206.00 2095.00 -42.43 3335.00 2694.00 23.79
Interest 155.00 187.00 -17.11 475.00 573.00 -17.10 752.00 564.00 33.33
PBDT 320.00 571.00 -43.96 351.00 1522.00 -76.94 2583.00 2130.00 21.27
Depreciation 412.00 332.00 24.10 1218.00 967.00 25.96 1344.00 1176.00 14.29
PBT -92.00 239.00 -138.49 -867.00 555.00 -256.22 1239.00 954.00 29.87
TAX -33.00 66.00 -150.00 -234.00 149.00 -257.05 330.00 259.00 27.41
Deferred Tax -33.00 21.00 -257.14 -234.00 22.00 -1163.64 30.00 -25.00 -220.00
PAT -59.00 173.00 -134.10 -633.00 406.00 -255.91 909.00 695.00 30.79
Equity 247.00 247.00 0.00 247.00 247.00 0.00 247.00 247.00 0.00
PBIDTM(%) 17.30 16.93 2.16 10.11 16.02 -36.92 17.93 15.10 18.79
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..